University College, London
Clinical trials sponsored by University College, London, explained in plain language.
-
New drug combo shows promise for tough head and neck cancers
Disease control CompletedThis early-stage trial tested adding the drug olaparib to standard chemotherapy and radiation for people with high-risk head and neck cancer. The goal was to find the safest dose and see how well patients tolerated the combination. Sixteen adults with advanced disease took part, …
Phase: PHASE1 • Sponsor: University College, London • Aim: Disease control
Last updated May 26, 2026 03:15 UTC
-
Could a diabetes drug be the key to slowing Parkinson's?
Disease control CompletedThis study tested whether exenatide, a drug already used for diabetes, can slow the progression of Parkinson's disease. About 194 people with early-stage Parkinson's took either exenatide or a placebo for 96 weeks. The goal was to see if the drug could protect nerve cells and red…
Phase: PHASE3 • Sponsor: University College, London • Aim: Disease control
Last updated May 26, 2026 03:12 UTC
-
Lung cancer study matches drugs to tumor DNA
Disease control CompletedThis study tested whether giving lung cancer treatments based on the genetic makeup of a person's tumor could improve outcomes. About 50 adults with non-small cell lung cancer that came back after initial treatment received either immunotherapy (atezolizumab) or targeted drugs li…
Phase: PHASE2 • Sponsor: University College, London • Aim: Disease control
Last updated May 26, 2026 03:04 UTC
-
New combo therapy shows promise for incurable head and neck cancer
Disease control CompletedThis study tested whether adding cetuximab to the immunotherapy drug avelumab works better than avelumab alone for advanced head and neck cancer that has returned or spread. The trial included a small safety check first, then planned to enroll 114 patients across UK hospitals. Tr…
Phase: PHASE2 • Sponsor: University College, London • Aim: Disease control
Last updated May 26, 2026 02:51 UTC
-
Immunotherapy shows promise in extending control of resistant ovarian cancer
Disease control CompletedThis study tested whether the immunotherapy drug pembrolizumab could help keep ovarian cancer from growing after initial chemotherapy. Twenty women with platinum-resistant ovarian, fallopian tube, or peritoneal cancer received weekly paclitaxel followed by pembrolizumab as mainte…
Phase: PHASE2 • Sponsor: University College, London • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Robot vs. Surgeon's hands: which bladder cancer surgery gets you home faster?
Disease control CompletedThis study compared two types of bladder removal surgery for people with bladder cancer: robot-assisted surgery and traditional open surgery. The main goal was to see which approach helped patients spend more days at home (alive and out of the hospital) in the first 90 days after…
Phase: NA • Sponsor: University College, London • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New hope for lymphoma patients who Can't tolerate standard chemo
Disease control CompletedThis study tested two different drug combinations for people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) who cannot take a common chemotherapy drug called anthracycline. The trial compared a newer drug (inotuzumab ozogamicin) plus standard therapy aga…
Phase: PHASE2 • Sponsor: University College, London • Aim: Disease control
Last updated May 19, 2026 11:46 UTC
-
New score could speed up care for severe appendicitis
Diagnosis CompletedThis study tested a scoring system called Appendistat (APS) to help doctors quickly identify patients with severe appendicitis who need urgent surgery. Researchers reviewed records of 592 patients who had their appendix removed and checked how well the score predicted complicated…
Sponsor: University College, London • Aim: Diagnosis
Last updated May 26, 2026 03:06 UTC
-
New drug could shield preterm lungs from chronic disease
Prevention CompletedThis study tested a new drug called rfhSP-D in 18 premature babies born before 30 weeks. The goal was to find the safest dose that might prevent chronic lung disease, a common problem in these infants. The drug was given within 12 hours of birth to babies already on a breathing m…
Phase: PHASE1 • Sponsor: University College, London • Aim: Prevention
Last updated May 26, 2026 03:11 UTC
-
New mental health program for Parkinson's aims to ease anxiety and depression
Symptom relief CompletedThis study tested a program of psychological interventions for mental health issues in people with Parkinson's, such as anxiety, depression, and thinking problems. The program was designed to be delivered by non-experts and included booklets for participants. 138 people with Park…
Phase: NA • Sponsor: University College, London • Aim: Symptom relief
Last updated May 26, 2026 03:13 UTC
-
Meditation study tests new way to ease PTSD and sleeplessness
Symptom relief CompletedThis study tested whether a guided meditation called yoga nidra can help people who have experienced trauma and struggle with insomnia and PTSD symptoms. Sixty adults were randomly assigned to a brief or full version of an 8-week online program, or a waitlist. Researchers measure…
Phase: NA • Sponsor: University College, London • Aim: Symptom relief
Last updated May 26, 2026 03:02 UTC
-
New app helps stroke patients regain lost words
Symptom relief CompletedThis study tested an app called iTALKBetter to help people who have trouble finding words after a stroke. 31 adults with aphasia used the app to practice naming pictures. The goal was to see if the app improved their ability to recall words they practiced compared to words they d…
Phase: NA • Sponsor: University College, London • Aim: Symptom relief
Last updated May 22, 2026 14:04 UTC
-
Stroke survivors see big gains with 90-hour arm rehab boot camp
Symptom relief CompletedThis study tested whether a three-week, 90-hour intensive arm therapy program helps people who had a stroke at least six months earlier. 105 participants were split into two therapy groups or a wait-list group that received usual care. The goal was to see if high-dose training im…
Phase: PHASE2 • Sponsor: University College, London • Aim: Symptom relief
Last updated May 22, 2026 14:04 UTC
-
New program aims to clear menopause brain fog without hormones
Symptom relief CompletedThis study tested a thinking skills program for women and others aged 40-60 going through menopause who experience 'brain fog'—trouble with memory, focus, and word recall. 33 participants used strategies to improve daily thinking. The goal was to see if the program was practical …
Phase: NA • Sponsor: University College, London • Aim: Symptom relief
Last updated May 22, 2026 14:01 UTC
-
Can vitamin e and a blood flow drug ease radiation scarring?
Symptom relief CompletedThis study tested whether taking pentoxifylline (a blood flow drug) and vitamin E together can help reduce scarring and tightness in the throat and jaw caused by radiation therapy for head and neck cancer. 50 adults who had radiation at least a year ago and were cancer-free took …
Phase: PHASE1 • Sponsor: University College, London • Aim: Symptom relief
Last updated May 22, 2026 13:50 UTC
-
Self-Compassion classes show promise for menopause mood swings
Symptom relief CompletedThis study looked at whether group compassionate mind training (CMT) is a practical and helpful option for adults going through menopause. 38 women aged 40-60 took part to see if the training could reduce feelings of self-criticism and improve mood and quality of life. The goal w…
Phase: NA • Sponsor: University College, London • Aim: Symptom relief
Last updated May 19, 2026 11:48 UTC
-
New app helps dementia patients recall loved Ones' names
Symptom relief CompletedThis study tested a web-based app called Gotcha! that helps people with mild-to-moderate dementia practice remembering names of people they know. 48 participants used the app at home for about 30 minutes each day over 6 weeks. The goal was to see if the app could improve name rec…
Phase: NA • Sponsor: University College, London • Aim: Symptom relief
Last updated May 18, 2026 12:00 UTC